Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | MERTK | Q12866 | 5/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14554770 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| SCHEMBL74518 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| SCHEMBL25804613 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| SCHEMBL6092812 | 0.81 | KEAP1 (1.00) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| SCHEMBL2535366 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| SCHEMBL24494597 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| SCHEMBL14638413 | 0.81 | KEAP1 (0.68) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL17184538 | 0.79 | KEAP1 (0.96) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28922912 | 0.79 | KEAP1 (0.66) | KEAP1DYRK1ADAOMEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL23201169 | 0.79 | KEAP1 (0.96) | KEAP1DYRK1ADAOMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | claimed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | claimed |
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024153595-A1 | CHROMANE DERIVATIVES AS EGFR SELECTIVE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-25 | — | — | WO | disclosed |
| CN-112867715-B | 5-azaindazole derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3870582-B1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| WO-2008014219-A2 | THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-5606061-A | HYPOTENSIVE AGENTS, ANTIASTHMATICS | EISAI CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| US-5498634-A | TREATING HYPERTENSION, ANGINA, ATP-SENSITIVE POTASSIUM CHANNEL AND ASTHMA | EISAI CO., LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| US-5444066-A | Thioformamide derivatives having hypotensive activity | EISAI CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0609442-A1 | THIOFORMAMIDE DERIVATIVE | Eisai Co., Ltd. (JP) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | KEAP1 2612/4885DYRK1A 1291/4885DAO 1916/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | KEAP1 316/4885DYRK1A 3341/4885DAO 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.